新型药物治疗和突破在牛皮关节炎治疗中的突破
Aiman Arraf1, Fadi Kharouf2,3,4, Dafna D Gladman3,4
1B. Shine Department of Rheumatology, Rambam Medical Center, Haifa, Israel.
Expert opinion on pharmacotherapy
|December 17, 2025
概括
牛皮性关节炎 (PsA) 的新疗法,包括生物药物和向抑制剂,提供了改进的管理. 代谢方法和个性化医学正在推动这种全身炎症疾病的治疗.
科学领域:
- 风湿病学和免疫学
- 药理学 药理学是指药理学的学科.
- 代谢疾病 代谢疾病
背景情况:
- 牛皮关节炎 (PsA) 是一种复杂的系统性炎症状况,影响关节,皮肤和其他组织.
- 这种病常常与肥胖,代谢综合征和心血管疾病等并发症有关.
- 尽管有当前的治疗方法,关节损伤和功能衰退仍然是患者面临的重大挑战.
研究的目的:
- 审查近期和新兴的治疗策略治疗牛皮关节炎.
- 讨论新型治疗方法的疗效,安全性和耐用性.
- 探索代谢向疗法和精密医学在PSA管理中的作用.
主要方法:
- 随机对照试验 (RCT) 和关于PsA疗法的观察性研究的综述.
- 分析新兴药物类别,包括生物DMARDs,TYK2抑制剂,JAK抑制剂和IL-23R向剂.
- 评估代谢向方法,如GLP-1RAs,用于肥胖的PsA.
主要成果:
- 像瑞桑基祖马布,比梅基祖马布,TYK2抑制剂和IL-17A/IL-17F纳米体这样的新疗法在各种领域的PSA管理中显示出希望.
- 代谢向疗法,特别是GLP-1RAs,对由肥胖驱动的PsA具有潜在的益处.
- 对于耐火性PsA病例,正在探索双通道向策略.
结论:
- 基于机制和代谢向治疗的进步促进了个性化的PsA管理和改善治疗目标的实现.
- 准确医学和以患者为中心的选择的未来进展预计将提高结果并减少疾病负担.
- 新兴的药物疗法正在扩大治疗选择,支持向更有效,更持久和更个性化的PsA护理迈进.
相关概念视频
Drug Therapy
232
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
232
Inflammatory Bowel Disease IV: Pharmacological Management
445
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
445
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
436
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
436
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
445
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
445
Psychosis: Goals of Pharmacotherapy
441
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
441
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
529
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
529


